Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$210.98 USD

210.98
262,278

-0.34 (-0.16%)

Updated May 14, 2024 04:00 PM ET

After-Market: $210.53 -0.45 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MDGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Madrigal Pharmaceuticals, Inc. [MDGL]

Reports for Purchase

Showing records 161 - 180 ( 184 total )

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

12/11/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

12/11/2017

Company Report

Pages: 9

Two Down, Two To Go, Increase PT; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

12/08/2017

Industry Report

Pages: 9

Healthcare -NASH Weekly: If You Love NASH, You''ll Love What''s to Come at JPM Healthcare

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

12/06/2017

Company Report

Pages: 7

MGL-3196 Hits Impressive Early Data in Intern POC NASH Readout; Raise PT to $105

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

12/06/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

12/06/2017

Company Report

Pages: 4

MGL-3196 Hits a Home Run with Phase 2b NASH Data

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

12/04/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

12/04/2017

Company Report

Pages: 7

Clear Your Mind and Begin the Countdown; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

11/30/2017

Company Report

Pages: 9

Let''s Deep Dive and Get Smart; Affirm Buy with Increased PT

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

11/30/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

11/29/2017

Company Report

Pages: 35

Novel Mechanism for Cardiometabolic Diseases: NASH and FH; Initiate Buy, $54 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 75.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

11/20/2017

Industry Report

Pages: 5

Healthcare -Takeaways from Our Expert Call With NASH Fibrosis Guru, Dr. Scott Friedman

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

11/10/2017

Company Report

Pages: 7

3Q17 Recap - Do Not Miss the Boat; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

11/03/2017

Industry Report

Pages: 7

Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

11/03/2017

Industry Report

Pages: 7

Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

10/31/2017

Industry Report

Pages: 4

Healthcare - NASH Is Hot and Getting Hotter! Dial-in to NASH Guru on Nov. 16 at 11:00 ET

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

10/30/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

10/30/2017

Company Report

Pages: 7

There Is Far More To Thyroid Hormone Receptor Modulation; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

10/27/2017

Industry Report

Pages: 11

Healthcare - NASH Weekly Newsletter: Do Not Miss Our Takeaways From The Liver Meeting

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

10/24/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party